FDA approves fewer new drugs in 2026 than 2027

The FDA will approve 10% fewer new drugs in 2026 compared to 2025 due to regulatory instability and staffing challenges. Industry uncertainty and turnover at the FDA will slow down approval timelines and increase scrutiny.

Implied probability (Yes)

70%

Closes

2027-12-31